Showing 4471-4480 of 5062 results for "".
- New PSA From American Academy of Dermatology Highlights Dangers of Tanninghttps://practicaldermatology.com/news/new-psa-from-american-academy-of-dermatology-highlights-dangers-of-tanning/2457753/As Memorial Day signals the unofficial start of summer, many teen girls will be eager to get out of school and spend time outside— and some may want to get a tan. But a new public service advertisement from the American Academy of Dermatology encourages those who are thinking of tanning to
- EWG: Two-Thirds of Sunscreen Products Offer Poor Protection or Have Worrisome Ingredientshttps://practicaldermatology.com/news/ewg-two-thirds-of-sunscreen-products-offer-poor-protection-or-have-worrisome-ingredients/2457756/The Environmental Working Group (EWG) released its 12th annual Guide to Sunscreens, rating the safety and efficacy of more than 1,000 sunscreens, moisturizers and lip balms that advertise sun protection, and found
- Castle Creek Pharmaceuticals Receives FDA Rare Pediatric Disease Designation for Diacerein 1% Ointment for EBhttps://practicaldermatology.com/news/castle-creek-pharmaceuticals-receives-fda-rare-pediatric-disease-designation-for-diacerein-1-ointment-for-eb/2457765/The FDA has granted rare pediatric disease designation for Castle Creek Pharmaceuticals' (CCP) diacerein 1% ointment (CCP-020) for the treatment of epidermolysis bullosa (EB). The safety and efficacy of CCP-020 is currently being evaluated in the DELIVERS study for the treatment of pat
- Aclaris to Support Symposium on JAK Inhibitors at the International Investigative Dermatology 2018 Meetinghttps://practicaldermatology.com/news/aclaris-to-support-symposium-on-jak-inhibitors-at-the-international-investigative-dermatology-2018-meeting/2457767/Aclaris Therapeutics, Inc. has provided an unrestricted educational grant for the symposium on Janus Kinase (JAK) inhibitors at the International Investigative Dermatology (IID) 2018 Meeting in Orlando, FL. The symposium, titled “JAKs Be Nimble: New Applications of JAK Inhibitors in Dermato
- Industry Vet James P. Hartman Named New Chief Commercial Officer at Alastinhttps://practicaldermatology.com/news/industry-vet-james-p-hartman-named-new-chief-commercial-officer-at-alastin/2457772/James P. Hartman is the new Chief Commercial Officer of Alastin Skincare, Inc.— effective May 14, 2018. Mr. Hartman recently served as Vice President & General Manager at Solta Medical, a division of Valeant Pharmaceuticals. Prior to Sol
- Sciton Announces New Leadership Teamhttps://practicaldermatology.com/news/sciton-announces-new-leadership-team/2457777/Sciton has an all new leadership team. The new Sciton leaders are: Aaron Burton, Chief Operating Officer Todd Sternbach, Vice President of Strategic Sales Initiatives David Percival, Vice President / General Manager of Sciton International Lacee Jacobson Na
- Tutublue Launches Men's Line of Sunsafe Activewearhttps://practicaldermatology.com/news/tutu-blue-launches-mens-line-of-sunsafe-activewear/2457780/Tutublue, the sun-protective activewear brand, is unveiling a line of men's rash guards and full suits for Summer 2018. Tutublue, designed by California actress and entrepreneur
- First Androgenetic Alopecia Patient Dosed in a Pilot Study with Aclaris' ATI-502 Topicalhttps://practicaldermatology.com/news/first-androgenetic-alopecia-patient-dosed-in-a-pilot-study-with-aclaris-ati-502-topical/2457795/Aclaris Therapeutics, Inc. initiated a Phase 2 open-label study of ATI-502, a topical Janus Kinase (JAK) 1/3 inhibitor (ATI-502 Topical), in patients with androgenetic alopecia (AGA), a condition characterized by a genetically determined male/female-pattern baldness. This trial will
- News You Can Use: Simple One-Page Tool Improves Patient Satisfaction with Doctor Visithttps://practicaldermatology.com/news/news-you-can-use-simple-one-page-tool-improves-patient-satisfaction-with-doctor-visit/2457805/A simple, one-page form given to patients ahead of time can significantly improve satisfaction with care, according to a study by Duke Health researchers. The low-tech tool, which asks for a list of the topics patients wants to discuss during their visit, helps patients focus on what&rsqu
- RealSelf Names Tanja Omeze Chief Marketing Officerhttps://practicaldermatology.com/news/realself-names-tanja-omeze-chief-marketing-officer/2457808/Ms. Tanja Omeze is RealSelf’s first ever chief marketing officer (CMO). As CMO, Ms. Omeze leads global marketing to increase awareness, engagement and connections among and between consumers and medical aesthetic professionals. Ms. Omez